Combination therapy for lingering leukemia after initial treatment
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of drugs (azacitidine, venetoclax, and a liposome form of chemotherapy) to see if it can clear tiny amounts of remaining leukemia in people who are already in remission after their first treatment. It aims to prevent the leukemia from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 59 years old.
- You must have completed your first round of chemotherapy as part of a specific myeloMATCH study and been assigned to this trial.
- Your leukemia must be in remission (no visible leukemia cells) but still show tiny amounts of disease on a sensitive test (called MRD).
- You must not have a FLT3 gene mutation (your doctor can check this).
- You must be able to swallow tablets and have no serious stomach or bowel problems that affect absorption.
- You must have adequate kidney and liver function, and if applicable, agree to use effective birth control during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This trial tests a combination of drugs for people with AML who, after initial treatment, have very low levels of leukemia still present (called measurable residual disease or MRD). The goal is to wipe out these remaining cells and reduce the chance of the cancer coming back.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This trial tests a new drug combo (tagraxofusp, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) who have very small amounts of cancer cells still present after initial treatment. The goal is to see if it can clear these leftover cells and prevent the cancer from coming back.
This study tests whether adding venetoclax to azacitidine after a patient reaches remission helps keep the leukemia from coming back. It is for people with acute myeloid leukemia (AML) who have completed initial treatment and are in their first remission.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.